Research records indexed for Dulaglutide
This page carries 12 of the 1,320 records that the literature query returned for Dulaglutide, selected by citation count and preferring records that name the compound in their title. It is a selection, not a complete index, and the 1,308 records it does not carry are not represented here. Every row resolves to a real identifier and names the study model, so no finding reads as a human claim by default. The compound page is Dulaglutide.
Indexed records
| Record | Year | Study type | Model | n as stated | What it reported |
|---|---|---|---|---|---|
| Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes pmid:41406444 | 2025 | Clinical Trial, Phase III, Equivalence Trial | human trial | Not stated | Indexed as clinical trial, phase iii, equivalence trial. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Blood Glucose; Recombinant Fusion Proteins; Injections, Subcutaneous. |
| Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics pmid:37758044 | 2024 | Clinical Trial Protocol, Research Support, Non-U.S. Gov't | other | Not stated | Indexed as clinical trial protocol, research support, non-u.s. gov't. study model from MeSH "Humans" with no interventional publication type. subject headings: Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents. |
| Effects of dulaglutide on alcohol consumption during smoking cessation pmid:37991022 | 2023 | research-article, Randomized Controlled Trial | human trial | Not stated | Indexed as research-article, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Alcohol Drinking; Smoking Cessation. |
| Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial pmid:35914543 | 2022 | Clinical Trial, Phase III, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as clinical trial, phase iii, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Body Weight; Gastric Inhibitory Polypeptide; Recombinant Fusion Proteins; Hypoglycemic Agents. |
| Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes pmid:35658022 | 2022 | Randomized Controlled Trial | human trial | Not stated | Indexed as randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Metformin; Blood Glucose; Recombinant Fusion Proteins; Hypoglycemic Agents. |
| Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11) pmid:33397768 | 2021 | Equivalence Trial, Research Support, Non-U.S. Gov't | human trial | Not stated | Indexed as equivalence trial, research support, non-u.s. gov't. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Metformin; Recombinant Fusion Proteins; Hypoglycemic Agents; Drug Therapy, Combination. |
| Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial pmid:32562683 | 2020 | Research Support, Non-U.S. Gov't, Multicenter Study | human trial | Not stated | Indexed as research support, non-u.s. gov't, multicenter study. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Immunoglobulin Fc Fragments; Glucagon-Like Peptides. |
| Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial) pmid:32865597 | 2020 | Research Support, Non-U.S. Gov't, Randomized Controlled Trial | human trial | Not stated | Indexed as research support, non-u.s. gov't, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Liver; Diabetes Mellitus, Type 2; Alanine Transaminase; Aspartate Aminotransferases; Recombinant Fusion Proteins. |
| Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial pmid:32333876 | 2020 | Clinical Trial, Phase III, Comparative Study | human trial | Not stated | Indexed as clinical trial, phase iii, comparative study. study model from MeSH "Humans" with publication type "clinical trial, phase iii". subject headings: Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Administration, Oral; Immunoglobulin Fc Fragments. |
| The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial pmid:31924562 | 2020 | Multicenter Study, Randomized Controlled Trial | human trial | Not stated | Indexed as multicenter study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetic Angiopathies; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents; Prospective Studies. |
| Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial pmid:31189511 | 2019 | Multicenter Study, Randomized Controlled Trial | human trial | Not stated | Indexed as multicenter study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Cardiovascular Diseases; Myocardial Infarction; Diabetes Mellitus, Type 2; Recombinant Fusion Proteins; Hypoglycemic Agents. |
| Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial pmid:31189509 | 2019 | Multicenter Study, Randomized Controlled Trial | human trial | Not stated | Indexed as multicenter study, randomized controlled trial. study model from MeSH "Humans" with publication type "randomized controlled trial". subject headings: Diabetic Nephropathies; Albuminuria; Diabetes Mellitus, Type 2; Creatinine; Recombinant Fusion Proteins. |
Where this page sits
Compound page: Dulaglutide. Class: Incretin receptor agonists.
Retrieved 2026-10-12.
Sources
- Drugs@FDA application register query for this compound, 1 application(s) returned: BLA125469. U.S. Food and Drug Administration, openFDA drugsfda endpoint (2026). fda:dulaglutide
- Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes care (2014). pmid:24842985
- Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes care (2014). pmid:24742660
- Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1). Diabetes care (2014). pmid:24879836
- Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet (London, England) (2014). pmid:25018121
- Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes care (2015). pmid:26089386
- Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. The lancet. Diabetes & endocrinology (2018). pmid:29483060
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet (London, England) (2019). pmid:31189511
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet (London, England) (2019). pmid:31189509
- Effect of dulaglutide on cognitive impairment in type 2 diabetes: an exploratory analysis of the REWIND trial. The Lancet. Neurology (2020). pmid:32562683
- Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. The lancet. Diabetes & endocrinology (2018). pmid:29910024
- Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The lancet. Diabetes & endocrinology (2018). pmid:29397376
On each stated value was matched to the record cited for it. That is record matching, not an appraisal of the research. Compiled and checked by: Peptide Monographs editorial desk. No qualified clinical reviewer.